Clinical trials
3 active studies led by Pulmovant, Inc., of 4 in all
Source: ClinicalTrials.gov, Studies with Pulmovant, Inc. (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
Free public records show Pulmovant, Inc. in 2 of the markets we cover. It is not a key player in our research.
[1] ClinicalTrials.gov, Studies led by Pulmovant, Inc. or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
3 active studies led by Pulmovant, Inc., of 4 in all
Source: ClinicalTrials.gov, Studies with Pulmovant, Inc. (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
Studies Pulmovant, Inc. leads, by the year they started and their phase
Source: ClinicalTrials.gov, Studies with Pulmovant, Inc. or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets we cover where free public records show Pulmovant, Inc.: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets Pulmovant, Inc. is in.
Stories on the topics Pulmovant, Inc. works in.
Omega-3 supplements are hugely popular. Big trials give mixed answers on whether they protect the heart.
Read
Cardiovascular disease is the world's leading cause of death, and stroke caused 11.9 million new cases in…
Read
Keeping the airway open is the first step in saving a life. More than half of deaths in low- and…
Read